Phase 4
Completed N=19
A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
Source: ClinicalTrials.gov NCT01035333 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Weight Loss — 2.0 percentage of weight
Summary
The primary goal of the study is to determine if orlistat 60mg (Alli) is effective in helping patients achieve a required 10% weight loss goal prior to bariatric surgery. The medication will be added to the usual standard of care which includes education regarding diet and exercise and monthly meetings with a registered dietician.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Weight Loss |
2.0 | — |
| SECONDARY Patient Satisfaction |
9 | — |
Eligibility Criteria
Inclusion Criteria
- adult patients preparing for gastric bypass surgery
Exclusion Criteria
- pregnancy
Data sourced from ClinicalTrials.gov (NCT01035333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.